{
  "guideline": {
    "id": "PA166170052",
    "name": "Annotation of FDA Label for valbenazine and CYP2D6",
    "objCls": "Label Annotation",
    "source": "FDA",
    "version": 18,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166170052",
    "relatedChemicals": [
      {
        "id": "PA166170051",
        "name": "valbenazine",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA128",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "symbol": "CYP2D6"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166312290",
      "name": "Recommendation Annotation PA166312290",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166170051",
          "name": "valbenazine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216551,
        "html": "<p>&quot;The recommended dosage for known CYP2D6 poor metabolizers is INGREZZA [valbenazine] 40 mg once daily.&quot; See label for more information</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product INGREZZA (Valbenazine), NDA209241, Neurocrine Biosciences, Inc.",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209241"
    }
  ],
  "version": "2024-03-08-14-34"
}